The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening

References

• Hennesy BT, Coleman RL, Markman M. Ovarian Cancer. Lancet. 2009;374:1371–1382.
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Meinhold-Heerlein I, Meinhold-Heerlien AI. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obs. 2014;290:839–842. doi:10.1007/s00404-014-3364-8
   PubMed Web of Science ®Google Scholar
• Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1–480.e8. doi:10.1016/j.ajog.2011.06.049
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and ovarian cancer: a comprehensive review. Cancers. 2020;12(12):3730. doi:10.3390/cancers12123730
   PubMed Web of Science ®Google Scholar
• Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170–177. doi:10.1056/NEJMcp0901926
   PubMed Web of Science ®Google Scholar
• Jacobs I, Prys Davies A, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br J Med. 1993;306(6884):1030–1034. doi:10.1136/bmj.306.6884.1030
   PubMedGoogle Scholar
• Bast RC, Klug TL, John ES, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med. 1983;309(15):883–887. doi:10.1056/NEJM198310133091503
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:1749–1760.
   Web of Science ®Google Scholar
• Zanaboni F, Vergadoro F, Presti M, et al. Tumor antigen CA125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol. 1987;28:61–67.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Mai P, Horick NK, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res. 2011;4:1401–1408. doi:10.1158/1940-6207.CAPR-10-0402
   PubMed Web of Science ®Google Scholar
• Urban N, Thorpe J, Karlan BY, et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol. 2012;21:2087–2094.
   PubMed Web of Science ®Google Scholar
• Erbagci AB, Yilmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA125 and CA 15-3 in healthy women. Dis Markers. 1999;15:259–267. doi:10.1155/1999/960934
   PubMed Web of Science ®Google Scholar
• Pauler DK, Menon U, Mcintosh M, et al. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomark Prev. 2001;10:489–493.
   PubMed Web of Science ®Google Scholar
• Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol. 2015;138:757–761. doi:10.1016/j.ygyno.2015.06.019
   PubMed Web of Science ®Google Scholar
• Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–277.
   PubMed Web of Science ®Google Scholar
• Akinwunmi BO, Babuc A, Vitonis AF, et al. Chronic medical conditions and CA125 levels among women without ovarian cancer. Cancer Epidemiol Biomark Prev. 2018;27:1483–1490. doi:10.1158/1055-9965.EPI-18-0203
   PubMed Web of Science ®Google Scholar
• Gupta A, Sagar G, Siddiqui Z, et al. A non-invasive method for concurrent detection of early-stage women specific cancers. Sci Rep. 2022;12:2301. doi:10.1038/s41598-022-06274-9
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Sundaramoorthy S, Gupta A, et al. Beta-validation of a non-invasive method for simultaneous detection of early-stage female-specific cancers. Biol Med. 2023;15:1. doi:10.35248/0974-8369.23.15.610
   Google Scholar
• Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:1
   PubMed Web of Science ®Google Scholar
• Funston G, Hamilton W, Abel G, et al. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoS Med. 2020;17(10):e1003295. doi:10.1371/journal.pmed.1003295
   PubMed Web of Science ®Google Scholar
• Gupta R, Mahajan S, Kaur S, et al. Demographic profile, staging and CA-125 levels in a patient with pelvic lesions of probable ovarian origin at presentation in a tertiary care hospital. Int J Adv Med. 2021;8:662–666. doi:10.18203/2349-3933.ijam20211472
   Google Scholar
• Khazael Z, Namayandeh SM, Beiranvand R, et al. Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods. J Prev Med Hyg. 2021;62:E174–E184.
   PubMedGoogle Scholar
• Scholler N, Urban N. CA125 in ovarian cancer. Biomarker Med. 2007;1:513–523. doi:10.2217/17520363.1.4.513
   PubMed Web of Science ®Google Scholar
• Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–3700.
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182–2193. doi:10.1016/S0140-6736(21)00731-5
   PubMed Web of Science ®Google Scholar